A systematic review and meta-analysis of pazopanib efficacy and adverse effects in sarcomas
Pazopanib demonstrated histology-specific efficacy in sarcomas, with a manageable toxicity profile. Furthermore, it does not appear inferior to non-placebo interventions, highlighting the need for further comparative studies to clarify its role in the therapeutic landscape of advanced sarcomas.
Authors
- Ottavia Clemente (ORCID: https://orcid.org/0000-0002-0569-8570)
- Antonio Pizzolorusso (ORCID: https://orcid.org/0000-0001-8238-0120)
- Mariachiara Santorsola
- L. Cannella (ORCID: https://orcid.org/0000-0002-9993-2013)
- Alessandra Bracigliano
- Ines Simeone
- Francesco Caraglia (ORCID: https://orcid.org/0009-0000-1853-9897)
- MD Salvatore Tafuto
- Antonella Lucia Marretta
- Michele Caraglia
- Fernanda Picozzi
- Giuseppina Della Vittoria Scarpati
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-02-02
- DOI
- https://doi.org/10.1186/s12967-026-07775-1
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Regione Campania